Clinical trials: Neuron Disease, Motor
Sialorrhea, Amyotrophic Lateral Sclerosis
Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea
Evaluation of the decrease of the secretion of saliva in patients with amyotrophic lateral sclerosis by a local ultrasound-guided bilateral injection of botulinum toxin type A in parotids and submandibular glands.
- Trial name
- ALS-TOX (NCT01551940)
- Testing
- Botox injection
- Where
- 13 sites in France
- Volunteers
- 18 people
- Sponsor
- Hospices Civils de Lyon
Amyotrophic Lateral Sclerosis
Brown Adipose Tissue in ALS
Weight loss is a common phenomenon in ALS. During the course of the disease, difficulty in swallowing and mastication can be responsible for a decrease in caloric intake and thus for weight loss.
- Trial name
- BATALS (NCT03150290)
- Testing
- Indirect Calorimetry., 18-FDG-PET
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Amyotrophic Lateral Sclerosis (ALS)
Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is an adult neurodegenerative disease that is caused by a selective degeneration of the motor nerve cells in the cortex and myelon.
- Trial name
- NCT00876772
- Testing
- Olanzapine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Amyotrophic Lateral Sclerosis
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
The purpose of this study is to assess the long-term safety and tolerability of reldesemtiv in patients with ALS who have successfully completed dosing in the Phase 3 clinical trial, CY 5031 (also known as COURAGE-ALS)
- Trial name
- NCT05442775
- Testing
- Reldesemtiv
- Where
- 41 sites in United States, Australia and 7 more
- Volunteers
- 71 people
- Sponsor
- Cytokinetics
Spinal Muscular Atrophy
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)
The primary objective of this study is to examine the clinical efficacy of nusinersen (ISIS 396443) administered intrathecally to participants with later-onset Spinal Muscular Atrophy (SMA).
- Trial name
- CHERISH (NCT02292537)
- Testing
- Nusinersen
- Where
- 24 sites in United States, Canada and 8 more
- Volunteers
- 126 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
This is an OLE study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical effects of WVE-004 in adult participants with ALS, FTD, or mixed ALS/FTD phenotype with a documented…
- Trial name
- NCT05683860
- Testing
- WVE-004 10 mg Q12W
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Wave Life Sciences USA, Inc.
Amyotrophic Lateral Sclerosis (ALS)
A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to investigate the safety and efficacy of long-term E0302 administration in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT00445172
- Testing
- E0302 (mecobalamin)
- Where
- 42 sites in Japan
- Volunteers
- 135 people
- Sponsor
- Eisai Co., Ltd.
Amyotrophic Lateral Sclerosis (ALS)
Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)
Neuroinflammation has recently emerged as a significant contributor to motor neuron damage. ALS tissue is characterized by inflammatory changes that are observed in both sporadic and familial ALS and in the ALS superoxide…
- Trial name
- NCT00231140
- Testing
- Thalidomide (drug)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Amyotrophic Lateral Sclerosis
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS
- Trial name
- NCT05633459
- Testing
- Multiple ascending doses of QRL-201, QRL-201
- Where
- 15 sites in Belgium, Canada and 4 more
- Volunteers
- 69 people
- Sponsor
- QurAlis Corporation
Amyotrophic Lateral Sclerosis
Tofacitinib in Patients With Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, of which motor-neuron's degeneration may be associated with neuroinflammation.
- Trial name
- TALENT (NCT06689982)
- Testing
- Tofacitinib tablets
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Tiantan Hospital
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)
MetFlex is an investigator led, open-label, single-arm, Phase 2a trial to determine the safety and tolerability of trimetazidine for the treatment of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND).
- Trial name
- MetFlex (NCT04788745)
- Testing
- Trimetazidine Dihydrochloride
- Where
- 3 sites in Australia, Netherlands and 1 more
- Volunteers
- 21 people
- Sponsor
- The University of Queensland
Spinal Muscular Atrophy
Development of a Multidisciplinary Network for Clinical and Laboratory Research for SMA
The goal of this observational study is to to establish profiles of clinical progression in patients affected by the different types of SMA (type I, II and III) treated with the currently approved drugs using a structured battery…
- Trial name
- NCT05866939
- Volunteers
- 400 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
AMYOTROPHIC LATERAL SCLEROSIS
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
The study aims to evaluate primarily safety of two injections of autologous mesenchymal stem cells in Amyotrophic Lateral Sclerosis patients. Secondary outcomes of efficacy will also be evaluated
- Trial name
- NCT02917681
- Testing
- Two intrathecal MSC injections
- Where
- Brazil
- Volunteers
- 28 people
- Sponsor
- University of Sao Paulo General Hospital
Metastatic Castration-Resistant Prostate Cancer
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
This study consists of a dose escalation study with an expansion phase to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and preliminary efficacy of exicorilant (CORT125281) in combination…
- Trial name
- NCT03437941
- Testing
- Exicorilant, Enzalutamide
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Corcept Therapeutics
Lateral Amyotrophic Sclerosis, Venous Thrombo-embolic Desease
Venous Disease Thromboembolic and Amyotrophic Lateral Sclerosis
Venous thrombo-embolic (VTE) rates could be high in patients with amyotrophic lateral sclerosis (ALS). Indeed, the rate of VTE in this specific population could be 7-fold higher in this population.
- Trial name
- TESLA (NCT04446325)
- Where
- France
- Volunteers
- 227 people
- Sponsor
- University Hospital, Brest
ALSFTD, ALS (Amyotrophic Lateral Sclerosis)
Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients
The aim of this study is to assess the impact of a probiotic formulation on participants with ALS-FTDSD. It is hypothesized that participants given the probiotics will have different lipid profiles compared to participants…
- Conditions
- ALSFTD, ALS (Amyotrophic Lateral Sclerosis), Frontal Temporal Dementia (FTD)
- Trial name
- PROBIOTIC (NCT06051123)
- Testing
- Probiotic
- Where
- 3 sites in Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Amyotrophic Lateral Sclerosis
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for people with a certain type of amyotrophic lateral sclerosis, also known as…
- Trial name
- NCT07223723
- Testing
- Tofersen
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Biogen
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Amyotrophic Lateral Sclerosis
Multidisciplinary Follow-up of Patients With Amyotrophic Lateral Sclerosis
Analyse a multidisciplinary follow-up of amyotrophic lateral sclerosis patients, monitored through a Cohort study at Geneva University Hospitals.
- Trial name
- NCT03536962
- Testing
- no intervention
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Ruxandra Iancu Ferfoglia
Tetraplegia, Locked-in Syndrome
Investigation on the Cortical Communication (CortiCom) System
The CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an external NeuroPort Neural Signal Processor.
- Conditions
- Tetraplegia, Locked-in Syndrome, Brainstem Stroke, Amyotrophic Lateral Sclerosis
- Trial name
- CortiCom (NCT03567213)
- Testing
- Surgical implantation of CortiCom system
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Johns Hopkins University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.